成功开发了铑催化的前手性取代苯并[ b ]噻吩1,1-二氧化物的不对称氢化反应,提供了各种手性2,3-二氢苯并[ b]]噻吩1,1-二氧化物,具有高收率和出色的对映选择性(高达99%收率和> 99%ee)。尤其是,对于具有挑战性的底物,例如具有空间位阻基团的芳基取代的底物和烷基取代的底物,反应在我们的催化体系中能顺利进行,并获得优异的结果。在催化剂负载为0.02摩尔%(S / C = 5000)的情况下,克级不对称氢化反应进展顺利,产率为99%,ee为99%。底物和配体之间可能的氢键相互作用可能在实现高反应性和出色的对映选择性中起重要作用。
首次成功开发了一种基于廉价过渡金属镍的高效催化体系,用于挑战性环状烯基砜,3-取代的苯并[ b ]噻吩1,1-二氧化物的不对称加氢。以高收率(95-99%)和优异的对映选择性(90-99%ee)获得了一系列氢化产物,手性2,3-二氢苯并[ b ]噻吩1,1-二氧化物。根据非线性效应研究,氘标记实验和DFT计算研究的结果,为这种镍催化的不对称氢化提供了合理的催化机理,表明该氢化产物中两个加成的氢原子可能来自H 2。 通过插入Ni–H和随后的氢解反应。
Enantioselective Hydroarylation or Hydroalkenylation of Benzo[<i>b</i>]thiophene 1,1-Dioxides with Organoboranes
作者:Fangdong Hu、Jie Jia、Ximing Li、Ying Xia
DOI:10.1021/acs.orglett.0c04114
日期:2021.2.5
protocol for the asymmetric hydroarylation and hydroalkenylation of benzo[b]thiophene 1,1-dioxides with organoboranes has been developed. The combination of a rhodium(I) precatalyst and a chiral diene ligand constitutes the catalytic system, which enables the facile synthesis of 2,3-dihydrobenzo[b]thiophene 1,1-dioxides in good yields with high enantioselectivities. The merging of this asymmetric hydroarylation
已开发出一种有效的方案,用于有机硼烷对苯并[ b ]噻吩1,1-二氧化物的不对称加氢芳基化和加氢烯基化反应。铑(I)预催化剂和手性二烯配体的组合构成了催化体系,该体系能够以高收率和高对映选择性轻松合成2,3-二氢苯并[ b ]噻吩1,1-二氧化物。该不对称氢芳基化与下游烷基化的合并以非对映异构的方式提供了包含两个具有高对映选择性的连续的季立体中心的2,3-二氢苯并[ b ]噻吩1,1-二氧化物。
[EN] FUCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE FUCOSIDASE
申请人:RAPTOR PHARMACEUTICALS INC
公开号:WO2017019925A1
公开(公告)日:2017-02-02
The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
In the compounds of Formula I, B or R
2
is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH
2
—.
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
In the compounds of Formula I, B or R
2
is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH
2
—.